Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-10RA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-10RA ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View IL-10RA Products |
| Gene Delivery | IL-10RA Premade ORF / Lentivirus Full-length ORF for stable cell lines. Co-expression compatible with IL-10RB. |
View IL-10RA Products |
| Benchmark Ab | Anti-IL-10RA Reference Antibody Recombinant positive control for binding & neutralization assays. Sequence Verified. |
View IL-10RA Products |
| Validator | IL-10RA siRNA Set For knockdown verification and specificity controls in cell-based assays. |
View IL-10RA Products |
| Co-Receptor | IL-10RB (CDw210b) Essential signaling subunit; required for high-affinity IL-10 complex formation and functional assays. |
View IL-10RB Products |
| Ligand | IL-10 (Interleukin-10) Native cytokine ligand for receptor binding, SPR, and competition assay development. |
View IL-10 Products |
| Off-Target Control | IL-22RA1 For selectivity screening; shared cytokine receptor family member (Type II) to exclude cross-reactivity. |
View IL22RA1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimeric Complex Formation (IL-10RA/IL-10RB) | Matched pair of ECD-Fc proteins with verified IL-10 binding kinetics; available as pre-mixed heterodimer complex for native conformation. |
| Cross-species Preclinical Evaluation (Human/Cyno/Mouse) | Ortholog proteins available for Human, Cynomolgus, and Mouse with >95% purity; sequence identity verified by Mass Spec. |
| Ligand Competition / Receptor Blocking | High-activity IL-10 protein included as standard control; validated blocking assay protocol available. |
| Cell Surface Expression Validation | Lentivirus particles with Puromycin selection marker; validated for Flow Cytometry detection on stable cell lines. |
| False Positives in Binding Assays | Validated siRNA included for specificity checks; IL-10RB counter-screen proteins and IL-22RA1 off-target controls available. |
Live IL-10RA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-10RA-targeted therapeutics is intensifying, with major players shifting focus from systemic recombinant IL-10 therapy to receptor-directed biologics, engineered cytokines, and bispecific modalities. First-generation PEGylated IL-10 (pegilodecakin) showed clinical limitations in solid tumor penetration, but its failure catalyzed a deeper understanding of the IL-10 pathway and highlighted the need for tissue-specific receptor modulation. The next wave of R&D is exploring both agonistic and antagonistic approaches: agonism for precision autoimmune therapy (e.g., IBD, psoriasis) and antagonism to reverse tumor-induced immunosuppression in the tumor microenvironment. Notably, specific IL-10RA mutations (e.g., rs1343534194, rs137853580 associated with IBD28, and rs4252250) have been linked to early-onset inflammatory bowel disease, underscoring the receptor's critical role in immune homeostasis. Future innovation will rely on spatial control of immune activation, biased signaling (partial agonism/antagonism), and combination therapies (e.g., with PD-1/PD-L1 checkpoint blockade).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Receptor Agonist mAb / Fusion Protein | Autoimmune-Focused Biotechs; next-gen muteins | IBD, Psoriasis, Rheumatoid Arthritis | Receptor Complex Binding (Need IL-10RA + IL-10RB heterodimer proteins) |
| Antagonist mAb | Oncology Biotechs (Phase I/II) | Solid Tumors (TME modulation) | Receptor Blockade Assay (Need high-purity IL-10RA/IL-10RB heterodimer for competition) |
| Bispecific (IL-10RA x Checkpoint) | Emerging platforms (Roche, Genmab) | Immunotherapy combinations | Heterodimer Validation (Need cross-reactive Abs & dual-antigen SPR) |
| Cell & Gene Therapy | Early-stage programs | Rare inflammatory disorders | Cell Surface Expression (Need full-length lentivirus for Flow Cytometry) |
| Small Molecule Inhibitors | Early discovery | Refractory inflammation | Selectivity Assay (Need IL-10RA vs IL-22RA1 counter-screen) |